As a key member of the Commercial Leadership Team, the ED will work cross-functionally with Commercial, Medical Affairs, Clinical Development, Regulatory, Finance, Legal/Compliance, Supply Chain, and external partners to ensure broad, timely, and appropriate patient access for a novel precision oncology therapy in a biomarker-defined patient population. This ED will be responsible for designing and building a fit-for-purpose market access organization and ensuring successful launch readiness across pricing, reimbursement, payer strategy, contracting, patient support services, distribution, trade, and evidence generation.